Accelerating Patient Access and $30M+ Therapy Value With Claritas Rx Patient Watchtower™ and Omnichannel CRM

A mid-sized U.S. pharmaceutical company supporting an oral oncology therapy faced persistent challenges with patient conversions and adherence. Lengthy decision times and out-of-stock delays were reducing first fill and refill rates, while coordination gaps among channel partners prevented timely patient support interventions.

• Low first fill rates for patients who waited over 21 days to make a therapy decision.
• Reduced refill rates for patients experiencing more than 41 days of out-of-stock delays.
• The need for seamless, coordinated action among multiple channel partners to ensure patients could start and stay on therapy at the right time.

• 4,500 intervention actions quarterly with sub-1-day partner response time: The client team maintained high system engagement, averaging 4,500 intervention actions per quarter and driving rapid channel partner response—typically under one day.
• +11–13 percentage point improvement in first fill rates: For patients with decision times exceeding 21 days, Claritas Rx Ascend® interventions boosted first fill rates by 11–13 percentage points.
• +13–25 percentage point increase in refill rates for out-of-stock cohorts: Patients facing out-of-stock periods longer than 41 days saw refill rate improvements of 13–25 percentage points, extending therapy continuity.
  Through these coordinated, data-driven interventions, the client added 2,211 incremental patient months on therapy (1,993 new fills, 218 refills)—generating total financial value exceeding $30 million.

Source: Claritas Rx, data on file, August 2025. Case study based on a mid-sized pharmaceutical company’s oral oncology drug.